Male Hypogonadism Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Male hypogonadism is a condition in which the body doesn’t produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, a decrease in muscle mass, and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles, and untreated sleep apnea. Treatment includes hormone replacement.
The Male Hypogonadism drugs in development market research report provide comprehensive information on the therapeutics under development for Male Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects.
Key Targets in the Male Hypogonadism Pipeline Products Market
The key targets in the Male Hypogonadism pipeline products market are Androgen Receptor, Estrogen Receptor, Follicle Stimulating Hormone Receptor, Voltage Dependent Anion Selective Channel Protein 1, Aromatase, Estrogen Receptor Beta, KiSS 1 Receptor, and Lutropin Choriogonadotropic Hormone Receptor.
Male Hypogonadism Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Male Hypogonadism Pipeline Products Market
The key mechanisms of action in the Male Hypogonadism pipeline products market are Androgen Receptor Agonist, Estrogen Receptor Antagonist, Follicle Stimulating Hormone Receptor Agonist, Voltage Dependent Anion Selective Channel Protein 1 Blocker, Aromatase Inhibitor, Estrogen Receptor Beta Antagonist, KiSS 1 Receptor Agonist, and Lutropin Choriogonadotropic Hormone Receptor Agonist.
Male Hypogonadism Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Male Hypogonadism Pipeline Products Market
The key routes of administration in the Male Hypogonadism pipeline products market are oral, nasal, transdermal, buccal, intramuscular, intravenous, and subcutaneous.
Male Hypogonadism Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Male Hypogonadism Pipeline Products Market
The key molecule types in the Male Hypogonadism pipeline products market are small molecule, peptide, recombinant protein, and synthetic peptide.
Male Hypogonadism Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Male Hypogonadism Pipeline Products Market
Some of the major companies in the Male Hypogonadism pipeline products market are IASO BioMed Inc, Met P Pharma AG, AbbVie Inc, Beijing FuKangren Bio-pharm Tech Co Ltd, Chong Kun Dang Pharmaceutical Corp, Diurnal Group Plc, Endoceutics Inc, Function Promoting Therapies LLC, Lennham Pharmaceuticals Inc, and Lipocine Inc.
Male Hypogonadism Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
Key targets | Androgen Receptor, Estrogen Receptor, Follicle Stimulating Hormone Receptor, Voltage Dependent Anion Selective Channel Protein 1, Aromatase, Estrogen Receptor Beta, KiSS 1 Receptor, and Lutropin Choriogonadotropic Hormone Receptor |
Key mechanism of action | Androgen Receptor Agonist, Estrogen Receptor Antagonist, Follicle Stimulating Hormone Receptor Agonist, Voltage Dependent Anion Selective Channel Protein 1 Blocker, Aromatase Inhibitor, Estrogen Receptor Beta Antagonist, KiSS 1 Receptor Agonist, and Lutropin Choriogonadotropic Hormone Receptor Agonist |
Key routes of administration | Oral, Nasal, Transdermal, Buccal, Intramuscular, Intravenous, and Subcutaneous |
Key molecule type | Small Molecule, Peptide, Recombinant Protein, and Synthetic Peptide |
Major companies | IASO BioMed Inc, Met P Pharma AG, AbbVie Inc, Beijing FuKangren Bio-pharm Tech Co Ltd, Chong Kun Dang Pharmaceutical Corp, Diurnal Group Plc, Endoceutics Inc, Function Promoting Therapies LLC, Lennham Pharmaceuticals Inc, and Lipocine Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).
- The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Beijing FuKangren Bio-pharm Tech Co Ltd
Chong Kun Dang Pharmaceutical Corp
Diurnal Group Plc
Endoceutics Inc
Function Promoting Therapies LLC
IASO BioMed Inc
Lennham Pharmaceuticals Inc
Lipocine Inc
M et P Pharma AG
Marius Pharmaceuticals LLC
Medlab Clinical Ltd
Merck & Co Inc
Mereo Biopharma Group Plc
MHB Labs
Solural Pharma ApS
TesoRx Pharma LLC
Transdermal Delivery Solutions Corp
Viramal Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Male Hypogonadism products market?
The key targets in the Male Hypogonadism pipeline products market are Androgen Receptor, Estrogen Receptor, Follicle Stimulating Hormone Receptor, Voltage Dependent Anion Selective Channel Protein 1, Aromatase, Estrogen Receptor Beta, KiSS 1 Receptor, and Lutropin Choriogonadotropic Hormone Receptor.
-
What are the key mechanisms of action in the Male Hypogonadism pipeline products market?
The key mechanisms of action in the Male Hypogonadism pipeline products market are Androgen Receptor Agonist, Estrogen Receptor Antagonist, Follicle Stimulating Hormone Receptor Agonist, Voltage Dependent Anion Selective Channel Protein 1 Blocker, Aromatase Inhibitor, Estrogen Receptor Beta Antagonist, KiSS 1 Receptor Agonist, and Lutropin Choriogonadotropic Hormone Receptor Agonist.
-
What are the key routes of administration in the Male Hypogonadism pipeline products market?
The key routes of administration in the Male Hypogonadism pipeline products market are oral, nasal, transdermal, buccal, intramuscular, intravenous, and subcutaneous.
-
What are the key molecule types in the Male Hypogonadism pipeline products market?
The key molecule types in the Male Hypogonadism pipeline products market are small molecule, peptide, recombinant protein, and synthetic peptide.
-
Which are the major companies in the Male Hypogonadism pipeline products market?
Some of the major companies in the Male Hypogonadism pipeline products market are IASO BioMed Inc, Met P Pharma AG, AbbVie Inc, Beijing FuKangren Bio-pharm Tech Co Ltd, Chong Kun Dang Pharmaceutical Corp, Diurnal Group Plc, Endoceutics Inc, Function Promoting Therapies LLC, Lennham Pharmaceuticals Inc, and Lipocine Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.